Corporate Profile  

Target Market 
 

Business Strategy
Our Story

Mission Statement

Officers & Key Personnel

Scientific Advisory Board

 

   
Ralph A. Bradshaw, Ph.D.  
  Ralph Bradshaw

Chair of Scientific Advisory Board

The scientific career of Dr. Ralph Bradshaw, a key advisor to CVBT, spans over 35 years. He is recognized as one of the world's foremost experts on protein biochemistry. Currently a professor in the Department of Physiology and Biophysics at University of California, Irvine, Dr. Bradshaw was Chair of the Department of Biological Chemistry at UC-Irvine for 10 years.

Dr. Bradshaw was the first president and founding father of the Protein Society, an organization of several thousand scientists dedicated to the study and analysis of proteins. In 1995, he was elected president of the Federation of American Societies for Experimental Biology (FASEB), one of the largest and most visible scientific societies in the United States.

In almost 300 publications in peer-reviewed scientific journals, Dr. Bradshaw has made important and significant contributions to our knowledge of the structure and function of proteins, and in particular, polypeptide growth factors. Prior to coming to California, Dr. Bradshaw served for 14 years as Professor of Biological Chemistry at the Washington University School of Medicine in St. Louis. He earned his Ph.D. in Biochemistry from Duke University in 1966, and his B.A. from Colby College in Maine.

 

< Back to Scientists

 

 

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.

 

12/11/2008
CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial


11/25/2008
CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease


11/13/2008
CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate


9/9/2008
CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial